PetVivo (PETV)

Search documents
PetVivo Engages Another Top Sales Manager, Cindy Gill, for Regional Business Development Manager, as Adoption of Breakthrough Animal MedTech Device Continues to Spread Nationwide
GlobeNewswire News Room· 2024-10-21 13:45
MINNEAPOLIS, MN, Oct. 21, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading provider of biomedical therapeutics for equines and companion animals, has appointed Cindy Gill to the position of field veterinary business development manager for the entire states of Oklahoma and Arkansas and the northern region of Texas. “Cindy’s experience and strong record of sales achievement with veterinary clinics brings to our sales team a valuable resource for achieving our business goals,” ...
PetVivo Meets Growing Demand for Spryng™ with Appointment of Veterinary Surgeon, Kirsty Husby, as Senior Technical Services Veterinarian
GlobeNewswire News Room· 2024-09-09 14:22
Expert Capablites of Senior Vet-Tech to Help Drive Greater Adoption of Spryng as Breakthrough Treatment of Osteoarthritis for Companiaon Animals MINNEAPOLIS, MN, & Annapolis Junction, MD, US, Sept. 09, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic devices for equines and companion animals, has appointed board certified veterinary surgeon, Dr. Kirsty Husby, DVM, MS, DACVS (LA), to the position of senior technical services ...
Scot Cave Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
GlobeNewswire News Room· 2024-09-03 14:27
MINNEAPOLIS, MN, US, Sept. 03, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Scot Cave has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover the Northwest Region of the United States. "The addition of Scot to our sales and distribu ...
Anthony Germinaro Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
GlobeNewswire News Room· 2024-08-19 14:10
MINNEAPOLIS, MN, US, Aug. 19, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Anthony Germinaro has accepted a position with the Company as its new Field Veterinary Business Development Manager for the for the Southwest Region of the United States. "Adding Anthony to our sales and distr ...
PetVivo (PETV) - 2025 Q1 - Earnings Call Transcript
2024-08-15 01:44
PetVivo Holdings, Inc. (OTCPK:PETV) Q1 2025 Earnings Call August 14, 2024 5:00 PM ET Company Participants John Dolan - Chief Business Development Officer and General Counsel John Lai - Chief Executive Officer Garry Lowenthal - Chief Financial Officer John Dolan Good afternoon, everyone. Thank you for joining us today to discuss PetVivo’s Results for its Fiscal First Quarter Ended June 30, 2024. Hosting the call today are the Chief Executive Officer of PetVivo, John Lai the company’s Chief Financial Officer, ...
PetVivo Reports Reports Fiscal Q1 2025 Results
GlobeNewswire News Room· 2024-08-14 20:25
Company Reieterates Gudience of 50% to 100% Revenue Growth in Fiscal 2025 MINNEAPOLIS, MN, US, Aug. 14, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, reported results for the fiscal first quarter ended June 30, 2024. All comparisons are to the same year-ago period unless otherwise noted. The company will hold a conference call at 5:00 p.m. Eastern time August 14, 2024 to ...
PetVivo (PETV) - 2025 Q1 - Quarterly Report
2024-08-14 20:00
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Mark One ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission File No. 001-40715 PetVivo Holdings, Inc. (Name of small business issuer in its charter) | --- | --- | --- | |--------------------------------- ...
Eric Samples Joins PetVivo Holdings, Inc. as a Field Veterinary Business Development Manager
GlobeNewswire News Room· 2024-08-12 17:52
MINNEAPOLIS, MN, US, Aug. 12, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV & PETVW) (the "Company") an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals and animal athletes is pleased to announce that Eric Samples has accepted a position with the Company as its new Field Veterinary Business Development Manager to cover Ohio, Pennsylvania, and the Baltimore/DC area of the United States. "We are incredibly e ...
PetVivo Sets Fiscal First Quarter 2025 Conference Call for Wednesday, August 14 at 5:00 p.m. ET
GlobeNewswire News Room· 2024-08-08 14:25
MINNEAPOLIS, MN, US, Aug. 08, 2024 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a leading biomedical company delivering innovative therapeutic medical devices for equines and companion animals, will hold a conference call on Wednesday, August 14, 2024 at 5:00 p.m. Eastern time to discuss results for the fiscal first quarter ended June 30, 2024. The financial results will be issued in a press release prior to the call. PetVivo management will host the presentation, followed by a question- ...
PetVivo (PETV) - 2024 Q4 - Annual Results
2024-06-28 20:50
"In fiscal 2024, we reported strong financial and operational progress, including revenues up 6% to $969,000," commented PetVivo CEO, John Lai. "Our revenue growth was driven largely by our expanded distributor network, with sales of Spryng™ by distributors up 15% to $732,000. This helped drive our gross profit up 6% to $740,000, with our gross margins improving 40 basis points to 76.3%. "Also during the year, we developed clinical data on the safety and efficacy of Spryng, increased distribution through th ...